ReviewNPJ Regenerative medicine2017
The malignant niche: safe spaces for toxic stem cell marketing.
Review in NPJ Regenerative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.Cytotherapy · 2024Article
- Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products.Stem cell reports · 2023Review
- ISSCR's Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventions.Stem cell reports · 2021Article
- Ethical and Practical Considerations for Integrating Cellular ("Stem Cell") Therapy into Clinical Practice.Current reviews in musculoskeletal medicine · 2020Review
- Regulation of Stem Cell Technology in Malaysia: Current Status and Recommendations.Science and engineering ethics · 2020Review
- Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research.NPJ Regenerative medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many tumors are sustained by microenvironments, or niches, that support and protect malignant cells, thus conferring a competitive advantage against both healthy cells and therapeutic interventions (for a brief review, see Yao and Link (Stem Cells 35: 3-8, 2017)). The global industry engaged in the commercial promotion of unproven and scientifically implausible cell-based "regenerative" therapies has developed a number of self-protective strategies that support its survival and growth in ways that are broadly analogous to the functions of the malignant niche.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.